# Spiriva® Assessment of FEV1 (SAFE)

> **NCT00277264** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 914 (—)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium (Spiriva®)

## Key facts

- **NCT ID:** NCT00277264
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 914 (—)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277264, "Spiriva® Assessment of FEV1 (SAFE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00277264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*